Lianren Health Named to Shanghai's Potential Unicorn List as City Surpasses 100 Entries for the First Time

Recently, Great Wall Strategic Consulting and the Administrative Committee of Suzhou Industrial Park jointly held“2022 China Potential Unicorn Enterprises Report”Press Conference: Unveiling the Latest Research Findings on China’s Potential Unicorn Enterprises.

This report shows that,In 2021, the total number of potential unicorn enterprises in China was 595, a year-on-year increase of 170., with a growth rate of 40.0%;359 newly established enterprises,The year-on-year growth rate was 44.8%.

From the perspective of regional distribution,“Beijing, Shanghai, Jiangsu, Guangdong, and Zhejiang” account for 83.0% of the total number of potential unicorns in China. Among them, Beijing firmly holds the top position nationwide, with nearly 150 potential unicorns;Shanghai ranks second, with 112 potential unicorns;Jiangsu ranks among the top three, with nearly 100 potential unicorns.

Potential unicorns are the reserve force of unicorn enterprises, as well as a new species with significant development potential and growth prospects. So,What is the total number and development status of potential unicorn enterprises in Shanghai? Why have these companies emerged in such large numbers?Let’s take a look together!

Potential unicorn enterprises refer to companies established within the past five years whose post-money valuation in their last round of financing has reached $100 million;Post-money valuation of the final funding round for companies established 5–9 years ago reached $500 million; companies that have received private equity investment and are not yet listed.

In recent years, potential unicorn enterprises in Shanghai have been emerging at an accelerated pace. According to the report,Shanghai’s Potential Unicorn Enterprises Surpass 100 for the First Time, with 70 New Additions.In 2021, 16 potential unicorn enterprises in Shanghai graduated to unicorn status, and 6 successfully completed their IPOs; Shanghai ranked first nationwide in both metrics.

From a regional distribution perspective, the 112 potential unicorn enterprises in Shanghai are distributed in a pattern resembling stars surrounding the moon.Of these, more than half are located in Pudong New Area, while the remaining enterprises are widely distributed across Minhang, Jiading, Lingang, Changning, Baoshan, Fengxian, Chongming, and other areas.

Specifically, PudongPotential unicorns account for the total number in Shanghai50.89%, a total of57households, with 43 in Zhangjiang and 8 in Lingang; secondly,Minhang has 13., accounting for approximately of the total number of enterprises in Shanghai11.61%; Jiading has 9, accounting for approximately of the total number of enterprises in Shanghai8.04%; Changning has 7, accounting for approximately of the total number of enterprises in Shanghai6.25%; Xuhui has 5，Accounting for approximately % of the total number of enterprises in Shanghai4.46%; Baoshan, Songjiang, Fengxian, and Chongming each have 3, each accounting for approximately of the total number of enterprises in Shanghai2.68%; Hongkou and Putuo each have 2,Each accounting for approximately of the total number of enterprises in Shanghai1.79%; Huangpu, Qingpu, Jinshan, and Yangpu each have one., each accounting for approximately of the total number of enterprises in Shanghai0.89%。

From the perspective of sector distribution,Shanghai’s 112 potential unicorn enterprises are distributed across29 Tracks, among which,RecentSeventy percent are distributed across the following key sectors: innovative drugs, innovative medical devices, in vitro diagnostics (IVD), integrated circuits, artificial intelligence, viral hit products, and corporate digital operations.

In the above data, Shanghai has 44 potential unicorns in the biopharmaceutical sector, ranking first in proportion.Among them,Innovative Drug Sector Companiesparticularly outstanding,The number reached 32.It became the hottest track for potential unicorns in Shanghai that year, accounting for 28.57% of the total number of enterprises across all tracks;There are eight companies in the innovative medical device sector,Accounting for 7.14%;There are four companies in the in vitro diagnostics (IVD) sector,Accounting for 3.57%.

Of these 44 potential unicorn companies in the biopharmaceutical sector, excluding those in Zhangjiang and Lingang, the other 15 are Huiyong Pharmaceutical, Zhengxu Bio, Insilico Medicine, Maijin Biotech, Ascendis Pharma (Shanghai), Aboz Medicine, Shanghai Cellular Therapy Group, Ecoceres Biotech, Yourui Pharma, Huihe Medical, Yixin Medical, Hanyu Medical, Lainuo Medical, Wentai Medical, and WuXi Apptec Diagnostics.

As industries receiving key support from Shanghai, integrated circuit and artificial intelligence enterprises have also demonstrated remarkable strength.8 potential unicorn companies in the integrated circuit sector,Accounting for approximately 7.14% of the total number of companies in the sector, the involved enterprises include MetaX, InnoGrit, StarFive, Zhiwei Semiconductor, Xingsi Semiconductor, ECHIPS, ChipON Information, and Axiomtek Semiconductor;The number of AI companies reached eight,Accounting for approximately 7.14% of the total number of companies in the sector, the involved enterprises include CloudPick, Zilliz, ThinkForce, Hubot Technology, Cyclone Robotics, ZhaoGuan Electronics, Leyan Technology, and Tianrang Intelligence.

Corporate Digital Operations TrackIn recent years, it has also shown a rapid rise, with the number of newly emerging potential unicorns this timeReaching 8 companies, accounting for approximately 7.14% of the total number of companies in the sector. The companies involved include Zhenyun Technology, Xiaoke Information, Seer Robotics, Datagrand, Woqu, Lixiaoyun, TakiTaki, and XYLink.

Furthermore,There are four companies in the robotics sector,Accounting for approximately 3.57% of the total number of companies in the sector, the involved enterprises include XYZ Robotics, Flexiv, Dajie Robot, and Quicktron.

Additionally,There are two companies each in the sectors of power batteries, new energy vehicles, autonomous driving, smart mobility, lifestyle services, and new retail.Each accounts for approximately 1.79% of the total number of companies in the sector. The companies involved are Weifu Energy and Jichong Hydrogen; Zhenqu Technology and Qianchen Auto; Xiantu Intelligence and BoLei Intelligence; Xiangdao Chuxing and Aotu Chuxing; Ririzhu and Wanyoo Internet Cafe; SENSER and Ushopal.

Furthermore,VR/AR, Industrial Internet, Industrial IoT, Big Data, High-End Intelligent Equipment and Components, Fintech, Clean Energy, Commercial Aviation, Digital Entertainment, Web Tools, Cloud Services, Smart Cities, Smart Logistics, Intelligent Connected Vehicles, and Smart Hardware each have one company., each accounting for approximately 0.89% of the total number of companies in the sector. The companies involved are HiAR, Shiheng Technology, Black Lake Technologies, Transwarp, Origin Cell Biology, Kaijing Group, Ideal Wanhui, Fengfei Aviation (AutoFlight), Midu Novel, Loudong Box, ZStack, Shanma Intelligence, Yazuoshou, Che Weishi, and PETKIT.

It is worth mentioning that,In recent years, the sector for viral hit products has seen rapid growth, with 10 companies emerging.Accounting for approximately 1.79% of the total number of companies in the sector, the involved enterprises include Wuye Banmian, Hutouju, Diluo Medical, Nowwa Coffee, Feizhi Milan, Daily Dark Chocolate, Yuefengtang, M Stand, Blokees, and NEIWAI.

Word Cloud of 112 Potential Unicorns in Shanghai

In 2021, the pool of potential unicorns in Shanghai’s innovative drug and medical device sectors continued to expand. This growth was primarily driven by the high level of internationalization in Shanghai’s biopharmaceutical industry and its leading R&D and innovation capabilities nationwide. Furthermore, the continuous optimization of the “Zhangjiang R&D + Shanghai Manufacturing” collaborative model has further fueled the sustained expansion of Shanghai’s cohort of potential unicorn enterprises.

As a National Comprehensive Science Center,Zhangjiang has 43 potential unicorns, accounting for 38.4%; Lingang has 8, accounting for 7.14%.

InZhangjiang: 43 CompaniesAmong potential unicorn enterprises,There are 19 innovative drug companies., including Mabwell, Yifang Biopharma, Stemirna, GenFleet Therapeutics, Lixin Pharma, Juntop Biotech, Everspin Bio, Caelum Biosciences, Saishen Pharmaceuticals, Rigor Medicine, Tongrun Biopharma, Akeso Biopharma, Zhengtengkang Biotech, Stardust Biotech, OrangeSail Pharma, Duchuang Medicine, Embody Therapeutics, Laekna, and Dipeptide Biologics.There are five integrated circuit enterprises,including InnoGrit, StarFive, Xingsi Semiconductor, E-Cores Communications, and ChipON Information.There are three digital health companies,Including LinkCare, Senyi Intelligence, and Lianren Health.There are three innovative medical device companies,Including Vascular Medical, Fourier Intelligence, and New Pulse Medical.There are three in vitro diagnostic (IVD) companies,Including Yeasen Biotechnology, Kuantai Genomics, and Mozhuo Biotechnology.There are 2 companies in digital operations., including DAGuan Data and Lixiaoyun.There is one company each in the fields of artificial intelligence, VR/AR, new energy vehicles, autonomous driving, high-end intelligent equipment and devices, network tools, smart hardware, and smart logistics.ZhaoGuan Electronics, Liangfengtai, Zhenqu Technology, Bolei Intelligence, YuanNeng Cell Biology, Loudong Box (Vulbox), PETKIT, and Platypus.

At8 in LingangAmong potential unicorn companies,There are four innovative drug companies.including Realing Biologics, ZhenGe Biotech, Yinno Bio, and Dinghang Pharma;There is one digital health company,It is Lianren Health;There are two integrated circuit enterprises,including MetaX Integrated Circuits and Axiomise Semiconductor;There is one smart city enterprise.It is Flash Horse Intelligence;There is one clean energy enterprise.It is Ideal Wanlihui.

First-time listeesLianren HealthThis is a health and medical big data industrial group with state-owned capital as the main body and equipped with market-oriented mechanisms. It implements the national strategies of “New Infrastructure” and “market-based allocation of production factors.” Based on its capabilities in aggregating and operating medical big data and conducting core scientific research, and supported by multiple technologies including cloud computing, big data, artificial intelligence, blockchain, and the Internet of Things (IoT), it leverages its advantages in data integration, governance, and application to actively develop various health and medical big data businesses across four major segments: consumers, healthcare, insurance, and pharmaceuticals.

Below is a comparative chart of the distribution of potential unicorn tracks in Zhangjiang and Lingang:

As typical representatives of hard-tech enterprises, China’s potential unicorns are playing an increasingly important role in leading new industry tracks, promoting high-quality regional economic development, and facilitating the transition from old to new growth drivers. Meanwhile, the rapid emergence of these potential unicorns is also a significant marker of the high-quality development of China’s new economy.

The robust growth of Shanghai’s potential unicorns highlights the rapid development of the city’s tech industry and new economy. Looking ahead, we are confident that Shanghai-based enterprises will continue to build on this momentum and achieve even more remarkable results!